We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

STRECK LABORATORIES

Develops and manufactures products for clinical and research laboratories in biotechnology, clinical controls, hemato... read more Featured Products: More products

Download Mobile App





Streck Introduces Three New Antibiotic Resistance Detection Kits

By LabMedica International staff writers
Posted on 06 Aug 2019
Streck Inc. More...
(La Vista, NE. USA), a supplier of blood collection tubes that standardize methods for sample collection, stabilization and transportation, showcased three new antibiotic resistance detection kits and the new RNA Complete BCT at the 2019 AACC Clinical Lab Expo.

Streck develops and manufactures laboratory products, specializing in biotechnology, clinical controls, hematology, immunology, flow cytometry, chemistry, urinalysis and quality control devices. Streck’s new ARM-D Kits detect the most clinically important current and emerging antimicrobial resistance threats. The kits ‒ now for MCR, expanded OXA, and TEM/SHV/GES ‒ rapidly screen more than 1,000 resistance gene variants. Streck’s ARM-D Kits include all five CRE gene families: KPC, OXA, NDM, IMP, and VIM. Colistin resistance target genes include MCR-1, MCR-2, MCR-3, MCR-4, and MCR-5. Streck’s ARM-D Kits are comprehensive, including targets for ampCs, as well as ESBLs.

Streck’s RNA Complete BCT is a direct draw whole blood collection tube that stabilizes the draw time concentration of exosomes and cell-free RNA. RNA Complete BCT prevents the release of exosomes from red and white blood cells and maintains cell-free RNA concentration for up to seven days at room temperature, allowing convenient sample collection, transport and storage.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Electrolyte Analyzer
BKE-B
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.